Skip to main content

Menu

BNF October 2022 Update

This update contains 7 significant changes, 4 dose changes, 2 new monographs, and 2 new preparations.

Significant changes:

  • Antibacterials, use for prophylaxis: updated guidance for the prevention of secondary cases of diphtheria, and addition of guidance for the prevention of intra-uterine infection in preterm prelabour rupture of membranes.
  • Daratumumab (Darzalex®): updated pregnancy advice.
  • Diphtheria vaccine: updated guidance for immunisation.
  • Gout: updated guidance on management.
  • Influenza vaccine: updated guidance for immunisation.
  • Obstetrics: updated guidance for preterm labour.
  • Valaciclovir [update to indication and doses in line with UK Health Security Agency recommendations on post-exposure prophylaxis for chickenpox and shingles].

Dose changes:

  • Aciclovir [update to indication and doses in line with UK Health Security Agency recommendations on post-exposure prophylaxis for chickenpox and shingles].
  • Colecalciferol [update to dosing for primary prevention and treatment of Vitamin D deficiency].
  • Ergocalciferol [update to dosing for primary prevention and treatment of Vitamin D deficiency].

  • Procyclidine hydrochloride [update to dosing for parkinsonism and drug-induced extrapyramidal symptoms].

New monographs:

  • Kimmtrak® [tebentafusp].
  • Scemblix® [asciminib].

New preparations:

  • Trimbow 172/5/9® [beclometasone with formoterol and glycopyrronium].
  • WockAIR® [budesonide with formoterol].

For further details on changes in the BNF click on https://www.medicinescomplete.com/#/content/bnf/PHP107699